阿尔茨海默病治疗药物的研究进展
Development of drug for Alzheimer′s disease
-
摘要: 阿尔茨海默病（Alzheimer′s disease，AD）是一种以严重的认知和记忆功能减退为临床表现的神经退行性病变。目前美国FDA批准的治疗AD的临床药物以调节神经递质为主，虽然能缓解症状，但疗效有限，难以逆转疾病进展。近年来，随着AD病理机制的进一步阐明，AD的药物研发取得了较大进展，并以开发能够有效延缓疾病进程及预防AD发生的药物为重点。其中以β淀粉样蛋白和tau蛋白为靶点开发的药物以及多种神经保护剂得到了广泛研究。目前多种候选化合物已经进入临床试验，为AD的治疗带来新的希望。根据药物作用靶点和机制，以上述几类药物为主，对目前AD的药物研究进展进行综述。Abstract: Alzheime′s disease (AD) is a heterogeneous neurodegenerative disease，which is characterized by severe memory deficits and cognitive impairment. Current FDA-approved drugs for AD aim at the correction of neurotransmitter abnormalities. They produce limited symptomatic effects but do not slow disease progression. During recent years，with the further understanding of the mechanisms that initiate and perpetuate AD，great progress has been made in the development of therapeutic drugs to reverse the disease course and prevent its initiation. Particularly，drugs targeting amyloid β and tau protein as well as neuroprotective reagents have been widely studied. Several promising candidates are currently under investigation in clinical trials，shedding new light on a disease-modifying therapy of AD. In this paper，the current status of the drug development for AD is reviewed，and the above-mentioned drugs classified according to their therapeutic targets are discussed.
-
Keywords:
- Alzheimer′s disease /
- therapeutic drugs /
- development
-
计量
- 文章访问数: 2334
- HTML全文浏览量: 14
- PDF下载量: 4207
下载:
